TX-FORTERRO
17.2.2021 10:02:16 CET | Business Wire | Press release
Forterro , a group of companies that deliver enterprise resource planning (ERP) software to small- and medium-sized businesses, today announced the appointment of two new executives to lead the company into a new phase of growth in its core market, Europe.
Dean Forbes, a longtime, U.K.-based software executive who was most recently the president of The Access Group, was named Forterro’s chief executive. Paul Smolinski, the former chief financial officer of HR and payroll software firm CoreHR, was named CFO. The two U.K.-based leaders have been tapped to continue Forterro’s growth strategy in Europe, working with the company’s strategic leadership teams across the group’s primary business units in France, Germany, Poland, Sweden, and Switzerland.
Forbes joins Forterro after an extensive career in executive and senior leadership roles for a number of international software companies. Most recently he led the growth and expansion of CoreHR, a UK HCM software provider, across Europe. CoreHR was acquired by The Access Group, where Forbes subsequently served as president and executive board member. Prior to CoreHR, Forbes was CEO of Paris-headquartered SaaS software company KDS, where he led the successful growth and international expansion of the firm, leading to its acquisition by American Express. Earlier in his career, Forbes held senior leadership roles at Philadelphia HQ’d Primavera Systems and, subsequently, Oracle where he was global vice president for sales and marketing for the PPM Division. Forbes brings this wealth of experience to Forterro and its acquired companies, which include abas Software (Germany); BPSC (Poland); Clip Industrie, Silog and Sylob (France); Jeeves and Infocube (Sweden); and ProConcept (Switzerland). Forterro is backed by global, technology-focused investment firm Battery Ventures.
“I am thrilled to become part of such a strong group of ERP companies, who are all successfully operating in one of the strongest, most steadily growing markets in enterprise software,” Forbes said. “The cornerstone of our ongoing success will be to continue investing in the market leadership positions of local and niche ERP software businesses throughout Europe. I am excited about leading the next stage of the Forterro journey as we look to continue to grow the business aggressively, both organically and through further acquisitions.”
“Bringing in new, Europe-based leadership is part of the natural evolution of Forterro,” said Dave Tabors, a Forterro board member and Battery Ventures private equity partner. “Former CEO Jeff Tognoni, former COO Scott Malia, and the rest of the U.S.-based Forterro leadership team have done an outstanding job of growing the business by evaluating, acquiring, and operating ERP companies. To push Forterro into its next stage of development, however, it is time to cultivate leadership talent in closer proximity to our business unit operations. We are very excited to work with Dean as he prepares Forterro for its next stage of growth.”
“We have spent the last several years working closely with our counterparts in Europe to build sustainable growth strategies and unique operating approaches for each business unit and product market,” added Jeff Tognoni, who is stepping down after leading Forterro and growing revenue more than seven-fold since the initial acquisition of Jeeves Information Systems in 2012. “The strength of our local teams and their businesses lets me know that part of our job is done, and that Forterro is ready for new challenges and continued success under the leadership of Dean and Paul.”
ABOUT FORTERRO
Forterro is a group of companies that deliver ERP software to SMEs in specialized geographical or vertical markets. Backed by the investment of Battery Ventures , Forterro operates business units in Sweden, Switzerland, France, Poland, and Germany, as well as regional office locations and research and development centers around the world. Through its ever-growing ecosystem of IP and capital, Forterro collaborates with local management teams to strengthen the solution offerings and operational performance of its portfolio companies. For more information, visit www.forterro.com .
ABOUT BATTERY VENTURES
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
